ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1132

DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk

Linrui Zhong, Tianyi Lei, Quanbo Zhang and Yufeng Qing, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Cell Death, gout, Inflammasome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Pyroptosis is closely linked to acute flare-ups and spontaneous remission of gout. However, the specific mechanisms by which pyroptosis regulates gout inflammation remain unclear. This study aims to analyze the potential role of DDX3X as a hub molecule influencing pyroptosis to regulate gout inflammation.

Methods: Bioinformatics methods were used to explore whether pyroptosis is involved in regulating gout. Real-time quantitative PCR (RT-qPCR), Western blotting (WB), and immunofluorescence were employed to assess DDX3X, ROS levels, and changes in the NLRP3/Caspase-1/GSDMD pathway. The regulation of pyroptosis mediated by DDX3X under different conditions was observed.

Results: Bioinformatics analysis revealed that pyroptosis is involved in gout regulation, identifying nine (pyroptosis-related genes)PRGs with DDX3X closely related to NLRP3. DDX3X was significantly overexpressed in acute gout patients. In the time-gradient model of gout inflammatory cells, both the classical pyroptosis pathway and DDX3X showed significant nonlinear characteristics, leading to trends in IL-1β changes, with DDX3X interacting with NLRP3. After DDX3X expression intervention, pyroptosis and gout inflammation showed characteristic changes. At the 3h oxidative damage stage, DDX3X participated in activating the NLRP3 inflammasome to promote pyroptosis. At the 9h oxidative stress stage, DDX3X might respond to stress granule assembly, indirectly inhibiting pyroptosis, thereby protecting cell survival. This protective mechanism might initiate negative feedback regulation to inhibit IL-1β release.

Conclusion: DDX3X can regulate gout inflammation by activating the NLRP3 inflammasome and mediating macrophage pyroptosis. It mainly participates in early inflammation in gout and cell homeostasis maintenance in the later stages of inflammation.

Supporting image 1Figure1. DDX3X and pyroptosis play an important role in gout inflammation

Supporting image 2Figure2. DDX3X and pyroptosis were differentially expressed in gout and were closely related to inflammation levels and oxidative stress

Supporting image 3Figure2. DDX3X contributes to gout inflammation by mediating pyroptosis through modulating NLRP3 inflammasome assembly


Disclosures: L. Zhong: None; T. Lei: None; Q. Zhang: None; Y. Qing: None.

To cite this abstract in AMA style:

Zhong L, Lei T, Zhang Q, Qing Y. DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/ddx3x-regulates-gout-inflammation-via-nlrp3-inflammasome-activation-and-macrophage-pyroptosis-crosstalk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ddx3x-regulates-gout-inflammation-via-nlrp3-inflammasome-activation-and-macrophage-pyroptosis-crosstalk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology